Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to Buy at Wall Street Zen

Key Points

• Kiniksa Pharmaceuticals International has been downgraded from a "strong-buy" rating to a "buy" rating by Wall Street Zen, despite several other analysts maintaining positive ratings and target increases for the stock.
• The company reported quarterly earnings that exceeded consensus estimates, with earnings per share of $0.23 and revenue of $156.80 million, indicating strong financial performance.
• Insider transactions showed significant selling activity, with top executives selling large amounts of their shares, reflecting a 41.15% reduction for the CFO and a 73.52% reduction for the COO.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other brokerages have also recently commented on KNSA. Wells Fargo & Company boosted their target price on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday, July 29th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of "Buy" and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Trading Up 0.1%

KNSA stock traded up $0.03 during trading on Friday, hitting $35.51. The company had a trading volume of 480,772 shares, compared to its average volume of 435,542. The business has a 50 day moving average of $30.79 and a 200 day moving average of $26.38. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 887.97 and a beta of 0.20. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $35.59.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, COO Eben Tessari sold 15,091 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $35.50, for a total value of $535,730.50. Following the completion of the transaction, the chief operating officer owned 44,452 shares in the company, valued at $1,578,046. This trade represents a 25.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider directly owned 57,403 shares in the company, valued at $1,868,467.65. This represents a 33.81% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 558,403 shares of company stock worth $18,078,671. 53.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at approximately $301,000. GAMMA Investing LLC boosted its stake in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Deutsche Bank AG raised its stake in Kiniksa Pharmaceuticals International by 177.1% during the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock valued at $8,762,000 after purchasing an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter valued at $1,184,000. Finally, Nuveen Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after purchasing an additional 54,361 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.